Get started
Author

M.E. Pérez López

Observed names: M. E. Pérez López, M. Eva Pérez López, M.E. Perez Lopez, M.E. Peréz Lopéz, Maria Eva Peréz Lopéz, María Eva Pérez López
OpenAlex ID: A5110194925
Guía de práctica clínica
2007 · José Abal Arca, Francisco Javier Barón Duarte, et al. · 59
Adenocarcinoma prostático y mieloma múltiple sincrónicos: a propósito de un caso
2007 · M.E. Pérez López, J. García Mata, et al. · Actas Urológicas Españolas · 9
PDF
SEOM clinical guidelines for the treatment of antiemetic prophylaxis in cancer patients receiving chemotherapy
2010 · Jesús García Gómez, M. Eva Pérez López, et al. · Clinical & Translational Oncology · 8
155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial
2023 · M. Oliveira, T. Pascual, et al. · ESMO Open · 5
PDF
60P Real-life use of Oncotype DX Breast Recurrence Score® test for the management of patients with node-negative and node-positive breast cancer in the autonomous community of Galicia (Spain)
2021 · I. Fernandez-Perez, S. Antolin Novoa, et al. · Annals of Oncology · 2
SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013
2013 · J. García Gómez, M. E. Pérez López, et al. · Clinical & Translational Oncology · 2
57TiP SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial
2022 · J. Balmana, T. Pascual, et al. · Annals of Oncology · 1
301P HER2DX in the modulation of HER2-positive early breast cancer (HER2+ eBC): A retrospective analysis
2025 · B. Alonso de Castro, S. Cobo, et al. · Annals of Oncology
195P Health-related quality of life outcomes in SOLTI VALENTINE: A trial of neoadjuvant HER3-DXd +/- letrozole for high-risk hormone receptor positive/HER2-negative early breast cancer
2025 · G. Villacampa, M. Oliveira, et al. · ESMO Open
PDF
Abstract OT1-08-08: CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2- metastatic breast cancer (MBC)
2020 · Sara Tolaney, Joanne Blum, et al. · Cancer Research
CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)
2019 · S.M. Tolaney, J.L. Blum, et al. · Annals of Oncology
Primary prevention and smoking habit among BRCA1/2 mutation carriers.
2019 · Patricia Cordeiro, Rocio Lesta, et al. · Journal of Clinical Oncology
Emesis y quimioterapia. Más allá de los setrones y los antagonistas del receptor NK1
2014 · Jesús García Gómez, M. E. Pérez López, et al. · Revisiones en cáncer
Tumor ovárico de células de la granulosa de tipo adulto. A propósito de un caso
2007 · M. Eva Pérez López, Jesús García Mata, et al. · Progresos de Obstetricia y Ginecología
Guía de práctica clínica. Cancro de pulmón e mesotelioma
2007 · José Abal Arca, Francisco Javier Barón Duarte, et al. · Dialnet (Universidad de la Rioja)
Tumor de células de la granulosa ovárico (TCG) juvenil: a propósito de un caso
2006 · M. E. Pérez López, J. García Mata, et al. · Oncología (Barcelona)
PDF
Paciente con cáncer colorrectal y tuberculosis: falso positivo en la PET y su repercusión clínica
2005 · M. Eva Pérez López, Jesús García Gómez, et al. · Medicina Clínica
Works count: 17
Citation count: 86
H-index: 4
I10-index: 1
Year
Topic
Type